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Medications for Constipation
(Based on U.S. Product Information)
Generic name

Common brands
(OTC/Rx status)

Adult dosage2,7,11-

Side effects2,7,11-14,16,17

14,16,17

Onset2,7,11-

Comments2,7,11-14,16,17

Cost*

14,16,17

Class: mechanism
Fiber/Bulk laxatives, oral: Increases stool bulk and GI motility, decreases colonic transit time. Bulk agents not helpful in managing opiate-induced constipation. Fiber contraindicated if obstructive
symptoms, or megacolon/megarectum. Must take at least 8 oz of fluid with each dose. Patients with esophageal narrowing shouldn’t take bulk laxatives.
Bran
Psyllium13

Metamucil and others
(OTC)

1 cup/day

Gas and bloating, iron & calcium malabsorption.

1 dose (volume
varies by
formulation) up to
tid. Mix with fluids.

Side effects same as bran. Psyllium can cause allergic
reactions. Do not use sugar-free formulations with
aspartame in phenylketonuria.

Up to 3 days
Psyllium decreases total
& LDL cholesterol, &
blood glucose. Give 2 h
before/after other drugs.

Metamucil:
$8-17

Granular psyllium products (Perdiem, etc) are deemed
unsafe and ineffective due to reports of esophageal
obstruction. Granular psyllium will be no longer be
marketed effective October 1, 2007.
Methylcellulose

Citrucel and others
(OTC)

Calcium
polycarbophil14

FiberCon tabs, powder,
and others (OTC)

1 dose (volume
varies with
formulation) up to
tid
2 tablets daily-qid

$30

Less bloating. Do not use sugar-free formulations with
aspartame in phenylketonuria. Can swell and cause
choking if taken dry or with inadequate fluids.
Side effects same as bran. Tablets can swell and cause
choking if taken with inadequate fluids.

Has calcium 244 mg/2
tabs. Take 1 hour before/
2 hours after tetracycline.

$18

Efficacy is marginal
when used alone for
treatment; role is
primarily prevention. Do
not take with mineral oil.

$36 brand
$8 generic

Stool softeners, oral: Decreased surface tension allows stool to absorb more water.
Docusate sodium
(formerly dioctyl
sodium sulfosuccinate)

Colace and others
(OTC)

100-300 mg/day
given daily or in
divided doses

Docusate calcium

Kaopectate Stool
Softener Liqui-Gel
(OTC)

240 mg daily

Liquid tastes bad.

Up to 3 days

$6

More. . .
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Common brands
Adult dosage2,7,11Side effects2,7,11-14,16,17
Onset2,7,11Comments2,7,11-14,16,17
14,16,17
14,16,17
(OTC/Rx status)
Hyperosmolar agents, oral: Increased intraluminal fluid. Sorbitol & lactulose are nonabsorbed disaccharides that are metabolized by colonic bacteria into organic acids.

Cost*

Sorbitol 70%

Generic (OTC)

15-30 mL daily-bid

Sweet taste, transient abdominal cramps, flatulence.

1-2 days

$43

Lactulose

Chronulac (RX)

15-30 mL daily-bid

Same as sorbitol; well-tolerated long-term.

1-2 days

Agent of choice in
hepatic failure.

$19-$73 generic

Polyethylene glycol
(PEG)

Golytely, Colyte, (RX)

8-32 oz daily. Chill
to improve taste.

Incontinence due to potency.

30-60 minutes
for large
doses before
GI procedures

Golytely, etc are
indicated for bowel
cleansing prior to
colonoscopy and barium
enema X-ray exams.

$45-$116

MiraLax15 (OTC)
GlycoLax (RX)

Fill bottle cap to
white line (17 g) or
use 1 heaping
tablespoonful daily.
Mix with 4-8 oz
liquid.

High doses can cause diarrhea, excessive stool
frequency, nausea, bloating, cramping, flatulence.

1-3 days

Do not use in kidney
disease unless under
supervision of a
physician (per OTC
product labeling).15

$25

Generic name

More. . .
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Common brands
Adult dosage2,7,11Side effects2,7,11-14,16,17
14,16,17
(OTC/Rx status)
Stimulants, oral: Alter electrolyte transport; stimulate myenteric plexus; increase motility.
Generic name

Bisacodyl

Senna (sennosides A
and B)16

Dulcolax, Correctol
(OTC) 5 mg entericcoated tablets
Senokot, Senokot S
(with docusate), others
(OTC)
Ex-lax (OTC)

Onset2,7,11-

Comments2,7,11-14,16,17

Cost*

Do not take po bisacodyl
until 1 hour after milk,
antacids, cimetidine.

$11.50

14,16,17

1-3 tabs daily

Incontinence, hyperkalemia, abdominal cramps.

6 hours

2 tabs daily up to
4 tabs bid

Malabsorption. ‘Cathartic colon’ with loss of
myenteric plexus neurons and muscularis propria
atrophy has been reported with chronic use.

6-12 hours

$32

2 tabs/pieces dailybid
Saline laxatives, oral: Osmotic gradient draws fluid into gut; cholecystokinin stimulated; decreased colon transit time.
Magnesium citrate17

Generic (OTC)

Magnesium hydroxide

Milk of Magnesia,
Haley’s M-O (with
mineral oil) (OTC;
liquid 400 mg/tsp)
Phillips Milk of
Magnesia tablets (OTC;
311 mg/tab)

Sodium phosphate18

Fleet Phospho-Soda
(OTC)

10 oz daily or
divided into two
5 oz doses/day
Drink a full glass
(8 oz) of water with
each dose.
15-30 mL daily-bid

$23

Hypermagnesemia in renal insufficiency; abdominal
cramps; diarrhea; gas.

0.5-3 hours

Hypermagnesemia in renal insufficiency; hyperphosphatemia leading to hypocalcemia; dehydration,
abdominal cramps, incontinence.

0.5-6 hours

Do not use longer than
one week without
consulting a physician.

$10

See labeling

Mix one
tablespoonful in
4 oz of cool water
(per 24 hours)
Drink at least an
additional full glass
(8 oz) of clear liquid
after each dose.

$60

$7

Hyperphosphatemia; hypocalcemia; hypernatremia,
calcium phosphate precipitation; nausea; vomiting;
diarrhea; hypotension; edema.
Acute phosphate nephropathy has been associated with
use.
Elderly, individuals with kidney disease or decreased
intravascular volume, and those using medications that
affect renal perfusion or functions (e.g., ACE
inhibitors, ARBs, diuretics, and possibly NSAIDs) are
at higher risk of acute phosphate nephropathy.19

0.5-3 hours

Avoid in kidney disease
or congestive heart
failure.
Do not exceed dose
unless advised by
physician.

More. . .
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Generic name

Common brands
(OTC/Rx status)

Lubricant laxatives, oral
Mineral oil (OTC)
Generic (OTC)

Adult dosage2,7,11-

Side effects2,7,11-14,16,17

14,16,17

15-45 mL/day

Onset2,7,11-

Comments2,7,11-14,16,17

Cost*

14,16,17

Lipid pneumonia; malabsorption of fat-soluble
vitamins including vitamin K in patients taking
warfarin (theoretical concern), dehydration,
incontinence.

6-8 hours

Do not take with
docusate; take on an
empty stomach.

$4-8

Avoid in neutropenia/
thrombocytopenia.

$6

Suppositories: Induce evacuation by local rectal stimulation.
Glycerin

Generic (OTC)

1 supp pr prn; can
take up to daily

Rectal irritation.

15-60 minutes

Bisacodyl

Dulcolax (OTC)

1 supp pr prn; can
take up to daily

Rectal irritation.

15-60 minutes

Incontinence, mechanical trauma.

6-8 hours

$36

Enemas: Evacuation induced by distended colon; mechanical lavage.
Mineral oil retention

(OTC)

100-250 mL/day pr

Tap water
Phosphate

Fleet (OTC)

Mechanical trauma.
5-15 minutes
Accumulated damage to rectal mucosa,
5-15 minutes
hyperphosphatemia, mechanical trauma.
Soap suds
1500 mL pr
Accumulated damage to rectal mucosa, mechanical
2-15 minutes
trauma.
Chloride Channel Activator: Enhance chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum.11
Lubiprostone20

Amitiza (RX)

500 mL pr
1 unit/day pr

24 mcg BID

Nausea, diarrhea, abdominal distension, abdominal
pain, flatulence, vomiting, loose stools.

Within 24
hours

Avoid in neutropenia/
thrombocytopenia.
Do not exceed
recommended dose.

$84
-$36
--

FDA approved for
treatment of chronic
idiopathic constipation in
adults.
Avoid in patients with
history of mechanical
gastrointestinal
obstruction and those
with severe diarrhea.

$197**

*Cost per 1 month supply at usual dose at http://www.drugstore.com. **Amitiza cost is AWP per McKesson.

Users of this document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on
the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and Internet
links in this article were current as of the date of publication.
More. . .
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Treatment Options for Constipation
The first step to treat most cases of
constipation is to provide more fiber, either as a
high-fiber diet or as supplements.1 Fiber laxatives
increase the frequency of bowel movements by
one to two per week.2 Fiber intake should be
increased gradually over seven to ten days,
starting with twice daily administration. The
Institute of Medicine recommends total daily fiber
intake of 38 grams for men and 25 grams for
women under the age of 50, and 30 grams for men
and 21 grams for women over the age of 50.3 In
most patients, the next step is to add an
inexpensive saline laxative such as milk of
magnesia. Stimulant laxatives, lactulose, and
polyethylene glycol are recommended if these
interventions fail. Sorbitol and lactulose have
similar efficacy, but their use is limited because
they cause gas.2 Some experts are recommending
polyethylene glycol, now available OTC, as an
alternative to saline laxatives such as milk of
magnesia or before stimulants such as senna or
bisacodyl for its benign side-effect profile. Longterm use of milk of magnesia has been associated
with electrolyte imbalances and should be
avoided in patients with renal dysfunction.
Stimulant laxatives are more likely to cause gas
and abdominal cramps. Concern has been raised
that long-term use of stimulant laxatives may
cause neurologic damage, but this is unproven.1
In clinical studies, plasma levels of polyethylene
glycol in patients with end-stage renal failure is
higher than in patients with normal renal function.
Although still considered a safe plasma level, the
OTC Miralax label warns against use in patients
with kidney disease unless supervised by a
physician.4
For
chronic
constipation,
psyllium,
polyethylene glycol, lactulose, or lubiprostone
(Amitiza) are recommended.5 Amitiza should be
reserved for individuals with chronic constipation
who don’t respond to or tolerate laxatives. There
is not enough evidence to support the use of stool
softeners, stimulant laxatives (e.g., senna,
bisacodyl),
milk of magnesia, calcium
polycarbophil, methylcellulose, or bran in chronic
constipation.
Both polyethylene glycol and
lactulose have sufficient evidence to support their
use in chronic constipation. Polyetheylene glycol

appears to be modestly more effective than
lactulose with few side effects.5 Lubiprostone is
the only prescription product approved by the
FDA for the treatment of chronic constipation.
Another
prescription
product,
Zelnorm
(tegaserod), also approved for chronic
constipation, was recently removed from the U.S.
market due to serious cardiovascular adverse
events such as angina, stroke, and heart attack.6
The National Cancer Institute recommends a
stimulant laxative in combination with a stool
softener for opiate-related constipation. Fiber
laxatives are not indicated in this situation.7 To
prevent constipation, a bowel program should be
started when opiate therapy begins, especially in
the elderly.4
When evaluating constipation, it is important
to consider drugs as contributors. Prescription
medications that can cause constipation include
opiates, anticholinergics, tricyclic antidepressants,
calcium channel blockers (primarily verapamil),
chemotherapy agents (vinca alkaloids), antiParkinsonian
agents,
sympathomimetics,
antipsychotics,
diuretics,
and
sedating
antihistamines. Over-the-counter agents that may
cause constipation include aluminum-containing
antacids, calcium supplements, iron supplements,
and antidiarrheal agents.1,2
A guideline for the management of
constipation in children is available from the
North
American
Society
for
Pediatric
Gastroenterology
and
Nutrition
at
http://www.naspghan.org/userassets/Documents/pdf/PositionPapers/constipatio
n.guideline.2006.pdf.
The different constipation treatment choices
are summarized in the previous table. With over
700 products on the market, it is impossible to list
them all. One must be careful when dealing with
brand names for these products. Brand extensions
mean that a product may not contain the active
ingredient usually associated with that brand. For
example, the Correctol brand name is used on
laxatives containing bisacodyl or docusate. The
Fleet brand name is used on bisacodyl tablets,
glycerin suppositories, and mineral oil or
phosphate enemas. The Phillips brand name is
used on products containing milk of magnesia,
More. . .
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docusate, and calcium polycarbophil.
The FDA recently ruled that granular
formulations
of
psyllium
(psyllium
[hemicellulose], psyllium hydrophilic mucilloid,
psyllium seed, psyllium seed [blond], psyllium
seed husks, plantago ovata husks, and plantago
seed) are not generally recognized as safe and
effective and are misbranded. The ruling was
based on reports of esophageal obstruction related
to the use of granular psyllium laxatives despite
efforts promoting safe use through label warnings
and directions. The ruling is effective October 1,
2007 and does not apply to psyllium containing
laxatives in other dosage forms, including
powders, tablets, or wafers.8

Conclusion
Approximately 4 million Americans have
frequent constipation.9 Lifestyle modifications
such as increasing dietary fiber and fluid intake,
and regular physical activity are generally
recommended before drug treatment to relieve
temporary constipation.9
When lifestyle
modifications fail to relieve constipation, overthe-counter laxatives can be used. Most over-thecounter laxatives are recommended not to be used
for longer than one week without consulting a
healthcare professional. A work up for secondary
causes of constipation should be done in patients
whose constipation is not relieved by over-thecounter laxatives, and who present with
concomitant symptoms such as nausea, vomiting,
weight loss, rectal pain, fever, cramping,
abdominal pain, anorexia, or family history of
inflammatory bowel disease or colon cancer.10
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.

Project Leaders in preparation of this DetailDocument:
Jill Allen, Pharm.D. (original
publication 2002), Joseph Woelfel, Ph.D., FASCP
(update 2005), Wan-Chih Tom, Pharm.D.,
(update May 2007).
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